Online citations, reference lists, and bibliographies.
← Back to Search

Recent Advances In Pulmonary Drug Delivery Using Large, Porous Inhaled Particles.

D. Edwards, A. Benjebria, R. Langer
Published 1998 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The ability to deliver proteins and peptides to the systemic circulation by inhalation has contributed to a rise in the number of inhalation therapies under investigation. For most of these therapies, aerosols are designed to comprise small spherical droplets or particles of mass density near 1 g/cm3 and mean geometric diameter between approximately 1 and 3 micron, suitable for particle penetration into the airways or lung periphery. Studies performed primarily with liquid aerosols have shown that these characteristics of inhaled aerosols lead to optimal therapeutic effect, both for local and systemic therapeutic delivery. Inefficient drug delivery can still arise, owing to excessive particle aggregation in an inhaler, deposition in the mouth and throat, and overly rapid particle removal from the lungs by mucocilliary or phagocytic clearance mechanisms. To address these problems, particle surface chemistry and surface roughness are traditionally manipulated. Recent data indicate that major improvements in aerosol particle performance may also be achieved by lowering particle mass density and increasing particle size, since large, porous particles display less tendency to agglomerate than (conventional) small and nonporous particles. Also, large, porous particles inhaled into the lungs can potentially release therapeutic substances for long periods of time by escaping phagocytic clearance from the lung periphery, thus enabling therapeutic action for periods ranging from hours to many days.
This paper references
10.1126/SCIENCE.276.5320.1868
Large porous particles for pulmonary drug delivery.
D. Edwards (1997)
10.1152/JAPPL.1979.47.4.867
Calculated deposition of inhaled particles in the airway generations of normal subjects.
T. Gerrity (1979)
10.1007/BF02477345
On the removal of air-borne droplets by the human respiratory tract: I. The lung
H. Landahl (1950)
10.1136/thx.41.5.364
Effect of aerosol particle size on bronchodilatation with nebulised terbutaline in asthmatic subjects.
M. M. Clay (1986)
10.1111/J.1748-1716.1990.TB08933.X
Permeability of the respiratory tract to different-sized macromolecules after intratracheal instillation in young and adult rats.
H. Folkesson (1990)
10.1378/CHEST.96.1.6
Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition.
M. Johnson (1989)
10.1021/AR00034A004
Polymer-controlled drug delivery systems
R. Langer (1993)
10.1016/S0168-3659(96)01579-9
Peptide delivery via the pulmonary route: a valid approach for local and systemic delivery
P. Smith (1997)
10.1016/0168-3659(93)90094-L
In vitro phagocytosis assay of nano- and microparticles by chemiluminescence. II: Effect of surface modification by coating of particles with poloxamer on the phagocytic uptake
S. Rudt (1993)
10.1016/0378-5173(94)00224-S
The optimal particle size for parasympathicolytic aerosols in mild asthmatics
P. Zanen (1995)
10.1016/0378-5173(79)90058-9
Separation and determination of four ergot alkaloids, dihydroergotameme-, dihydroergocornine-, dihydroergocryptine- and dihydroergocristine methanesulfonates by high performance liquid chromatography
S. L. Ali (1979)
10.1093/ANNHYG/10.3.161
The Deposition of 0·5 µ Diameter Aerosols in the Lungs of Man
D. Muir (1967)
10.1016/0168-583X(84)90395-1
Aerosol deposition in the human respiratory tract
J. W. Winchester (1984)
10.3109/9781420003260
Inhalation Studies: Foundations and Techniques
R. Phalen (1984)
10.1016/0021-8502(94)90189-9
Modelling the deposition of inhaled powdered drug aerosols
A. R. Clark (1994)
10.3109/9781420019537-18
Aerosol generation from propellant-driven metered dose inhalers
A. Hickey (1995)
10.1016/0021-8502(84)90007-7
Mathematical models of particle deposition in the human respiratory tract
J. Heyder (1984)
10.1615/CRITREVTHERDRUGCARRIERSYST.V12.I2-3.20
Delivery of biotherapeutics by inhalation aerosol.
R. Niven (1995)
10.1073/PNAS.86.2.680
Fate of aerosolized recombinant DNA-produced alpha 1-antitrypsin: use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance.
R. C. Hubbard (1989)
10.1016/0378-5173(94)90070-1
Drug delivery to the respiratory tract using dry powder inhalers
M. P. Timsina (1994)
10.1201/9780203912898.ch3
Targeting by deposition
I. Gonda (1992)
10.1378/CHEST.80.6.904
The preferential deposition of inhaled isoproterenol and propranolol in asthmatic patients.
R. Ruffin (1981)
10.1016/0168-3659(94)90155-4
Bioavailability of pulmonary delivered peptides and proteins: α-interferon, calcitonins and parathyroid hormones
J. Patton (1994)
Uptake and transport of exogenous proteins by respiratory epithelium.
J. Richardson (1976)
10.1016/0021-8502(75)90020-8
Total deposition of aerosol particles in the human respiratory tract for nose and mouth breathing
J. Heyder (1975)
10.1002/JBM.820221002
Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers.
Y. Tabata (1988)
10.1002/JEMT.1070260510
Surfactant and inhaled particles in the conducting airways: Structural, stereological, and biophysical aspects
P. Gehr (1993)
10.1016/b978-0-08-042029-5.x5000-4
Aerosol Science for Industrial Hygienists
J. Vincent (1995)
10.3109/10717549509031346
Pulmonary Absorption of Peptides and Proteins
D. Wall (1995)
10.1152/JAPPL.1972.32.5.591
Breathing of half-micron aerosols. I. Experimental.
C. N. Davies (1972)
10.2337/diab.20.8.552
Insulin Across Respiratory Mucosae by Aerosol Delivery
F. W. Wigley (1971)
10.1016/0142-9612(88)90033-6
Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage.
Y. Tabata (1988)
10.1016/0169-409X(95)00113-L
Mechanisms of macromolecule absorption by the lungs
John S. Patton (1996)
10.1016/0378-5173(94)90436-7
The optimal particle size for β-adrenergic aerosols in mild asthmatics
P. Zanen (1994)



This paper is referenced by
10.1080/01902140303775
PULMONARY DEPOSITION OF MONODISPERSE AEROSOLS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
T. Meyer (2003)
10.1007/s00125-006-0161-3
Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes
S. Garg (2006)
10.14356/KONA.2008011
Applications of the Atomic Force Microscope in the Development of Propellant-based Inhalation Formulations
Libo Wu (2008)
Microsferas de polisacáridos y lípidos para la administración pulmonar de macromoléculas terapéuticas
Dayamí Carrión Recio (2013)
10.1039/C002158J
Microfluidic generation of a high volume fraction of bubbles in droplets
Jiandi Wan (2010)
10.1128/AAC.50.4.1552-1554.2006
In Vivo Efficacy of Aerosolized Nanostructured Itraconazole Formulations for Prevention of Invasive Pulmonary Aspergillosis
B. J. Hoeben (2006)
10.1016/J.EJPB.2004.04.018
Spray freezing into liquid nitrogen for highly stable protein nanostructured microparticles.
Zhongshui Yu (2004)
10.2165/00024677-200504030-00001
Inhaled Insulins
I. Harsch (2005)
10.1038/nrd2153
Inhaling medicines: delivering drugs to the body through the lungs
John S. Patton (2007)
10.1016/J.SUPFLU.2016.04.001
Design of experiments approach on the preparation of dry inhaler chitosan composite formulations by supercritical CO2-assisted spray-drying
R. P. Cabral (2016)
10.1111/j.2042-7158.2012.01486.x
Engineered PLGA nano‐ and micro‐carriers for pulmonary delivery: challenges and promises
F. Ungaro (2012)
PULMONARY TARGETING EMPLOYING POROUS PARTICULATES
SHWETA B HADKE (2012)
10.1002/JPS.10152
Factors affecting the deposition of inhaled porous drug particles.
C. J. Musante (2002)
10.2165/00151829-200605010-00004
Antioxidant Strategies in Respiratory Medicine
M. Christofidou-Solomidou (2006)
10.1201/9780849379741.PT3
Self-Assembly of Nanostructures as Biomaterials
Hua Ai (2008)
10.1051/EPJCONF/20146702006
Comparison of methods for evaluation of aerosol deposition in the model of human lungs
M. Bělka (2014)
10.1208/s12249-020-01735-8
Development, In Vitro Characterization, and In Vivo Toxicity Evaluation of Chitosan-Alginate Nanoporous Carriers Loaded with Cisplatin for Lung Cancer Treatment
Mo’tasem M. Alsmadi (2020)
10.1016/J.POWTEC.2013.01.037
Preparation and characterization of quercetin-loaded solid lipid microparticles for pulmonary delivery
L. F. C. Silva (2013)
10.1007/s00063-006-1065-1
Möglichkeiten und Probleme der Applikation von systemisch wirksamen, höhermolekularen Wirkstoffen mittels Inhalation*
G. Wichert (2006)
10.1016/j.ejpb.2004.03.008
PLGA–PEI nanoparticles for gene delivery to pulmonary epithelium
M. Bivas-Benita (2004)
10.1016/j.ejpb.2010.05.002
Secondary cytotoxicity mediated by alveolar macrophages: a contribution to the total efficacy of nanoparticles in lung cancer therapy?
K. Al-Hallak (2010)
Influence des propriétés physicochimiques du principe actif et du transporteur sur la performance aérodynamique des mélanges de poudre pour inhalation
Van Phuong Le (2011)
Investigating the delivery of antimicrobial proteins and aminoglycoside antibiotics to the airways
Wilson Oguejiofor (2013)
10.1016/j.rmr.2010.04.004
Inhaled insulin: a model for pulmonary systemic absorption?
M. Becquemin (2010)
10.1016/j.colsurfb.2014.07.020
Combination of doxorubicin-based chemotherapy and polyethylenimine/p53 gene therapy for the treatment of lung cancer using porous PLGA microparticles.
Xiaozheng Shi (2014)
10.1016/J.POWTEC.2012.03.006
Influence of lactose carrier particle size on the aerosol performance of budesonide from a dry powder inhaler
Waseem Kaialy (2012)
The relevance of solid state properties of aminoglycoside antibiotics to dry powder dispersion in a DPI
M. Hoppentocht (2016)
10.1016/S0168-3659(03)00325-0
In vitro and in vivo evaluation of the effects of PLA microparticle crystallinity on cellular response.
D. L. Biggs (2003)
10.1201/9780203912898.CH17
Recent Advances Related to the Systemic Delivery of Therapeutic Molecules by Inhalation
J. Man (2003)
FACTORS AFFECTING PULMONARY TARGETING OF INHALED CORTICOSTEROIDS
K. Wu (2006)
10.1208/aapsj0902021
Characterization of a cyclosporine solid dispersion for inhalation
G. Zijlstra (2008)
10.1002/ADMA.200800628
Controllable Microfluidic Production of Microbubbles in Water‐in‐Oil Emulsions and the Formation of Porous Microparticles
Jiandi Wan (2008)
See more
Semantic Scholar Logo Some data provided by SemanticScholar